Page 19 - பாரிங் ப்ரைவேட் பங்கு ஆசியா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

HK-based buyout firm Baring to invest $100m in Chinese drug maker Hutchmed Source: Michael Longmire/Unsplash April 9, 2021 Hong Kong-based buyout firm Baring Private Equity Asia has agreed to purchase $100 million worth of shares in Hutchison China MediTech (Hutchmed), a US- and London-listed, commercial-stage, biopharmaceutical firm that aims to treat cancer and immunological diseases. Baring, one of Asia’s largest private equity (PE) investment houses, plans to acquire nearly 3.28 million American depositary shares (ADS) in Hutchmed at $30.5 apiece through a private placement, according to a statement on Thursday. Baring is joining Hutchmed’s major shareholders, including US-based investment manager Capital Group, insurer Prudential, and global PE powerhouse General Atlantic, to fund the firm’s ongoing research and clinical development.

United statesHong kongCity ofUnited kingdomMeditech hutchmedChristian hoggCapital groupDrug administrationAsia private equity fundHong kong basedBaring private equity asiaHutchison china meditechGeneral atlanticKong based hutchmedNew drug applicationAsia pacific